Immuneering Corp Cl A (IMRX) Stock Price, Quote & News

Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Cor...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8080

Website: immuneering.com

Address:

245 Main Street, Second Floor, Cambridge, United States

HubAllianceModern Mar. 21 at 6:30 PM

$IMRX is on my list, just following along.

0 · Reply

MASTER_CHIEF__117 Mar. 21 at 3:00 PM

$IMRX setting up here - Let's see that sitrep data - Stock is worth 16.00

0 · Reply

putsandcalls Mar. 21 at 4:43 AM

$IMRX tried to be smart ass by taking a nickel with 15 mins left and stock at 4.75.prob called away

0 · Reply

AlwaysBullish99 Mar. 20 at 10:58 PM

$IMRX The heavy selling at the close is very abnormal for IMRX. Excited for Q2

1 · Reply

JuggernautRaider Mar. 20 at 10:51 PM

$IMRX hope you have been buying dips too @Night_Owl_Biotech 🏦

0 · Reply

longDstyle Mar. 20 at 8:22 PM

$IMRX massive volume spike the last 30 minutes. 7.3 million shares traded , and 6.5 million was in 30 minutes. Anyone know what’s going on?

1 · Reply

longDstyle Mar. 20 at 6:36 PM

$IMRX one of the only stocks on the market that is holding up

0 · Reply

dcrown Mar. 20 at 3:13 PM

$IMRX adding more , strong today

0 · Reply

longDstyle Mar. 20 at 2:30 PM

$IMRX one of the easiest trades of 2026 here

0 · Reply

watchaddict Mar. 20 at 1:38 PM

$IMRX 1000 more I am going to disney land when this one binks

0 · Reply

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

Mar 6, 2026, 7:45 AM EST - 15 days ago

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 2, 2026, 4:05 PM EST - 19 days ago

Immuneering to Present at the Leerink Global Healthcare Conference

Feb 18, 2026, 4:05 PM EST - 4 weeks ago

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 8, 2026, 5:45 PM EST - 2 months ago

Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data

Jan 8, 2026, 9:28 AM EST - 2 months ago

Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower

Jan 7, 2026, 6:47 PM EST - 2 months ago

Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript

Jan 7, 2026, 4:00 PM EST - 2 months ago

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Dec 23, 2025, 8:00 AM EST - 3 months ago

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Dec 17, 2025, 4:05 PM EST - 3 months ago

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Dec 16, 2025, 8:00 AM EST - 3 months ago

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Nov 25, 2025, 8:00 AM EST - 4 months ago

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 9:11 PM EST - 4 months ago

Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:05 PM EST - 4 months ago

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Nov 4, 2025, 4:05 PM EST - 4 months ago

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Sep 29, 2025, 4:37 PM EDT - 6 months ago

Immuneering Corporation - Special Call

Sep 26, 2025, 4:01 PM EDT - 6 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Sep 25, 2025, 2:19 PM EDT - 6 months ago

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Sep 25, 2025, 12:08 AM EDT - 6 months ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Sep 24, 2025, 4:05 PM EDT - 6 months ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Sep 24, 2025, 4:01 PM EDT - 6 months ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Sep 16, 2025, 7:00 AM EDT - 6 months ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 10, 2025, 7:00 AM EDT - 6 months ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Aug 26, 2025, 4:05 PM EDT - 7 months ago

Immuneering Announces Closing of $25 Million Private Placement

Aug 25, 2025, 8:00 AM EDT - 7 months ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Aug 21, 2025, 8:00 AM EDT - 7 months ago

Immuneering Announces $25 Million Private Placement

Aug 13, 2025, 4:05 PM EDT - 7 months ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 9, 2025, 8:00 AM EDT - 9 months ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jun 17, 2025, 6:00 AM EDT - 9 months ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 16, 2025, 8:00 AM EDT - 9 months ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

May 29, 2025, 8:00 AM EDT - 10 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

May 5, 2025, 4:05 PM EDT - 11 months ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Immuneering Corporation Announces Grant of Inducement Award

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Feb 3, 2025, 4:05 PM EST - 1 year ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 7, 2025, 9:28 AM EST - 1 year ago

Why Is Immuneering Stock Trading Higher On Tuesday?

Dec 19, 2024, 8:00 AM EST - 1 year ago

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 13, 2024, 2:10 PM EST - 1 year ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

FOLD

Dec 12, 2024, 8:00 AM EST - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

May 7, 2024, 4:05 PM EDT - 2 years ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 4:30 PM EDT - 2 years ago

Immuneering Recognizes Melanoma Awareness Month

Apr 9, 2024, 12:00 PM EDT - 2 years ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 3, 2024, 4:05 PM EDT - 2 years ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

HubAllianceModern Mar. 21 at 6:30 PM

$IMRX is on my list, just following along.

0 · Reply

MASTER_CHIEF__117 Mar. 21 at 3:00 PM

$IMRX setting up here - Let's see that sitrep data - Stock is worth 16.00

0 · Reply

putsandcalls Mar. 21 at 4:43 AM

$IMRX tried to be smart ass by taking a nickel with 15 mins left and stock at 4.75.prob called away

0 · Reply

AlwaysBullish99 Mar. 20 at 10:58 PM

$IMRX The heavy selling at the close is very abnormal for IMRX. Excited for Q2

1 · Reply

JuggernautRaider Mar. 20 at 10:51 PM

$IMRX hope you have been buying dips too @Night_Owl_Biotech 🏦

0 · Reply

longDstyle Mar. 20 at 8:22 PM

$IMRX massive volume spike the last 30 minutes. 7.3 million shares traded , and 6.5 million was in 30 minutes. Anyone know what’s going on?

1 · Reply

longDstyle Mar. 20 at 6:36 PM

$IMRX one of the only stocks on the market that is holding up

0 · Reply

dcrown Mar. 20 at 3:13 PM

$IMRX adding more , strong today

0 · Reply

longDstyle Mar. 20 at 2:30 PM

$IMRX one of the easiest trades of 2026 here

0 · Reply

watchaddict Mar. 20 at 1:38 PM

$IMRX 1000 more I am going to disney land when this one binks

0 · Reply

wealthystar Mar. 20 at 4:45 AM

$IMRX buying more

0 · Reply

longDstyle Mar. 19 at 10:20 PM

$IMRX added more today. It should creep up before the April 17yh conference

0 · Reply

watchaddict Mar. 19 at 3:35 PM

$IMRX 500

0 · Reply

watchaddict Mar. 19 at 1:40 PM

$IMRX 1000 more

0 · Reply

watchaddict Mar. 19 at 1:34 PM

$IMRX ADDING LFG

0 · Reply

longDstyle Mar. 19 at 3:57 AM

$IMRX I’ve been adding more and more . Easy money if you hold for bit

0 · Reply

Uatu616 Mar. 19 at 12:52 AM

$IMRX all this good news is killing me

0 · Reply

ZacksResearch Mar. 18 at 1:49 PM

$IMRX to present new molecular data on atebimetinib at AACR 2026, highlighting a novel mechanism aimed at improving durability and survival in cancer patients 👀 The data will show that its Deep Cyclic MEK inhibitor may reduce resistance by limiting MAPK pathway alterations in RAS-mutant tumors, with analysis from 64+ patients suggesting more sustained anti-tumor activity versus traditional approaches. With a Phase 3 pancreatic cancer trial expected to begin mid-2026, IMRX continues to build momentum around its differentiated oncology platform 💊 📊 Price target breakdown here 👇 https://www.zacks.com/stock/research/IMRX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-37372&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_37372

1 · Reply

focafoca99 Mar. 17 at 9:38 PM

$IMRX is bringing molecular data from atebimetinib-treated patients to AACR, and they are tying it back to durability and survival

0 · Reply

OptimistJP Mar. 17 at 9:34 PM

$IMRX More insider buying on March 13 Neufeld Leah R 3,628 A $4.2925

0 · Reply

rickahuna Mar. 17 at 9:04 PM

$IMRX Current Institutional Ownership Percentage 67.65% Number of Institutional Buyers (last 12 months) 62 Total Institutional Inflows (last 12 months) $104.01M Number of Institutional Sellers (last 12 months) 9 Total Institutional Outflows (last 12 months) $2.96M Even Renaissance took some ownership in February It's auspicious

0 · Reply

JuggernautRaider Mar. 17 at 8:54 PM

$DERM appreciate the heads up @hofno2003 . I need to do a deep dive on Emrosi. This may join my Top Ten Biotech list along with $ALT $IMRX and of course $TNXP

0 · Reply

Market Cap	309.04M
Revenue (ttm)	0.00
Net Income (ttm)	-56.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	7,292,700
Avg Vol	1,685,810
Day's Range	N/A - N/A
Shares Out	64.65M
Stochastic %K	30%
Beta	0.46
Analysts	Strong Sell
Price Target	$17.00